

CORRECTION

OPEN



Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Sophia Ceder , Sofi E. Eriksson, Ying Yu Liang, Emarndeena H. Cheteh, Si Min Zhang , Kenji M. Fujihara , Julie Bianchi , Vladimir J. N. Bykov , Lars Abrahmsen, Nicholas J. Clemons , Pär Nordlund, Sean G. Rudd and Klas G. Wiman

© The Author(s) 2022

Cell Death and Disease (2022)13:672; <https://doi.org/10.1038/s41419-022-05130-y>

Correction to: *Cell Death & Disease* <https://doi.org/10.1038/s41419-021-03988-y>, published online 15 July 2021

The original version of this article was unfortunately missing additional information in the legend of figure 3. The following sentences should be added at the end of the legend to Fig. 3: The same GAPDH control blot is shown in panels F and J since both xCT (F) and ASNS (J) were examined on the same blot. The blot was divided into an upper part which was probed with ASNS antibody and a lower part which was probed with xCT antibody and then re-probed with GAPDH antibody. Thus, the same GAPDH blot serves as control for both xCT and ASNS. The legends to the Supplementary figures were also missing. The original article has been corrected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022